Ultragenyx (RARE) Stock Price Target Raised After Gene Therapy Approval

Cantor Fitzgerald has raised its price target for Ultragenyx Pharmaceutical Inc. (RARE) following the recent approval of its gene therapy. The exact new price target was not disclosed in the article. The approval of this therapy could potentially increase the company's revenue and market presence. Investors should note that the updated price target reflects a growing confidence in Ultragenyx's product pipeline.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.